Use of Immunohistochemically Demonstrated c-erb B-2 Oncoprotein
Expression as a Prognostic Factor in Transitional Cell Carcinoma
of the Urinary Bladder

Lipponen, P; Eskelinen, M; Syrjänen, Stina; Tervahauta, Arja; Syrjänen, Kari

doi:10.1159/000471706

Cited by 40 publications

(23 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Other authors reported an overall positive immunoreactivity ranging between 12% and 47% [19,24,32,40,43,51,58,68]. Expression was correlated with the grades and stages, high-grade and high-stage more frequently positive than low-grade and low-stage TCC, confirming the results of previous studies [15,19,24,25,47,51,58,59].…”

Section: Immunohistochemical Findingssupporting

confidence: 83%

Histogenesis of nonurothelial carcinomas of the urinary bladder from pre-existent transitional cell carcinomas. A histopathological and immunohistochemical study

Kunze

Francksen

2002

Urological Research

View full text Add to dashboard Cite

The histogenesis of nonurothelial carcinomas of the urinary bladder is difficult to understand, since the bladder is normally lined exclusively by transitional cell epithelium. To gain more insights into the pathogenesis of nonurothelial carcinomas, the morphology and immunohistochemistry of transitional cell carcinomas (TCC), mixed transitional cell and nonurothelial carcinomas, and pure nonurothelial carcinomas were comparatively studied. Of papillary and of nonpapillary (solid) TCC (overall incidence 6.8%), 4.8% and 15.4%, respectively, disclosed foci of altered celllular and architectural phenotypes, consisting of squamous epithelium, pseudoglandular formations, and true glands with or without mucus production. The diverse phenotypic variants develop obviously by a metaplastic process as a result of the well-known inherent potential of the urothelium to undergo several pathways of cellular differentiation. There is strong evidence that squamous cell carcinomas arise secondarily from a squamous metaplasia and adenocarcinomas from metaplastic glandular epithelium within pre-existing TCC following complete carcinogenic transformation of the initially bland-looking metaplastic tumor cells. The metaplastic origin of nonurothelial bladder carcinomas is supported by immunohistochemical findings. The high molecular weight cytokeratin 34betaE12 identifies tumor cells with squamous characteristics, helping to explain the development of squamous cell carcinomas. Secretion of MUC5AC apomucin is assumed to play a central role in the histogenesis of nonurachal mucus-producing adenocarcinomas, including signet ring cell carcinomas. Metaplastic phenotypic variants of TCC should be recognized as distinct tumor entities with the potential to transform into nonurothelial carcinomas and thus possibly implying a poorer clinical outcome than typical, uniform TCC.

show abstract

Section: Immunohistochemical Findingssupporting

confidence: 83%

Histogenesis of nonurothelial carcinomas of the urinary bladder from pre-existent transitional cell carcinomas. A histopathological and immunohistochemical study

Kunze

Francksen

2002

Urological Research

View full text Add to dashboard Cite

show abstract

“…HER2/neu overexpression is less common in superficial TCC [341] and lower grade tumors [335]. HER2/neu overexpression is associated with poor prognosis [332,[342][343][344] and one third to one half of TCCs with overexpression have gene amplification [330,334,336,337].…”

Section: Urinary Tractmentioning

confidence: 99%

HER2/neu: an increasingly important therapeutic target. Part 2: Distribution of HER2/neu overexpression and gene amplification by organ, tumor site and histology

Nelson¹

2014

Clinical Investigation

View full text Add to dashboard Cite

No biological molecule in the field of oncology has been more extensively or more successfully targeted for therapeutic intent than the product of the c-erbB2 gene, HER2/neu. This is the second of a comprehensive three-part review of the foundation for and therapeutic targeting of HER2/neu. The distribution of HER2/neu overexpression and/or gene amplification by individual tumor sites and histologies will be comprehensively surveyed and described. This provides a bridge between the primarily basic science focused Part I, and the survey of clinical applications to follow in Part III. In combination, this comprehensive survey will identify opportunities and promising areas for future evaluation of HER2/neu-targeted therapies, highlighting the importance of HER2/neu as an increasingly important therapeutic target.

show abstract

“…Most of the recent analyses of prognostic factors in transitional cell cancer of the bladder (TCC) have evalu ated quantitative [1][2][3][4][5][6] and immunological methods [6,7], Particularly DNA ploidy [1,3,5], S-phase fraction [4], mitotic indices [2][3][4] and nuclear factors [1. 3, 5] have been extensively studied as indicators of prognosis.…”

Section: Introductionmentioning

confidence: 99%

“…3, 5] have been extensively studied as indicators of prognosis. The prognostic value of blood group antigens [6] has been known for a long time and recently other marker mole cules of prognostic value have also been found [7], How ever, several clinical variables are significant predictors in TCC including the clinical stage, which is the main deter minant of prognosis in mixed cohorts of patients [1-4, 8. 9], There are also other clinical factors affecting survival in TCC as well as in other neoplastic diseases.…”

Section: Introductionmentioning

confidence: 99%

Clinical Prognostic Factors in Transitional Cell Cancer of the Bladder

et al. 1993

Self Cite

View full text Add to dashboard Cite

A cohort of 537 patients with transitional cell cancer of the bladder (TCC) were followed up for a mean of 9 years and the clinicopathological data were related to prognosis. The T category (p < 0.0001), N category (p < 0.0001) and M category (p < 0.0001) were the most important clinical prognostic factors, followed by the age of the patient (p < 0.0001). Of the histological variables the WHO grade (p < 0.0001), papillary status (p < 0.0001) and the presence of R3–4 cells in voided urine (p = 0.0061) predicted unfavorable prognosis. In Ta–T1 tumors the WHO grade (p < 0.0001), papillary status (p < 0.0001) and the age of the patient (p < 0.0001) had a prognostic value in univariate analysis. In Cox’s analysis independent predictors of survival were the T category (p < 0.0001), WHO grade (p < 0.0001), patient age (p < 0.0001), papillary status (p = 0.012) and the presence of symptoms before diagnosis (p = 0.033). In superficial tumors the WHO grade (p < 0.0001) and patient age (p < 0.0001) were independent predictors of survival.

show abstract

Use of Immunohistochemically Demonstrated c-erb B-2 Oncoprotein Expression as a Prognostic Factor in Transitional Cell Carcinoma of the Urinary Bladder

Cited by 40 publications

References 4 publications

Histogenesis of nonurothelial carcinomas of the urinary bladder from pre-existent transitional cell carcinomas. A histopathological and immunohistochemical study

Histogenesis of nonurothelial carcinomas of the urinary bladder from pre-existent transitional cell carcinomas. A histopathological and immunohistochemical study

HER2/neu: an increasingly important therapeutic target. Part 2: Distribution of HER2/neu overexpression and gene amplification by organ, tumor site and histology

Clinical Prognostic Factors in Transitional Cell Cancer of the Bladder

Contact Info

Product

Resources

About